Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity
Expert Opinion on Drug Delivery, 2023•Taylor & Francis
Objectives The focus of the present research is to develop printlet formulations of
pyrimethamine (PMT). Methods Printlets formulation of PMT were developed by screening
design by varying laser scanning speed, Kollidon® VA 64, polyvinylpyrrolidone, and
disintegrant. Results Laser scanning speed, Kollidon® VA, and disintegrant had statistically
significant effect on hardness, disintegration time, and/or dissolution (p< 0.05). Dissolution
was almost 100% in 30 min. X-ray powder diffraction indicated partial amorphous …
pyrimethamine (PMT). Methods Printlets formulation of PMT were developed by screening
design by varying laser scanning speed, Kollidon® VA 64, polyvinylpyrrolidone, and
disintegrant. Results Laser scanning speed, Kollidon® VA, and disintegrant had statistically
significant effect on hardness, disintegration time, and/or dissolution (p< 0.05). Dissolution
was almost 100% in 30 min. X-ray powder diffraction indicated partial amorphous …
Objectives
The focus of the present research is to develop printlet formulations of pyrimethamine (PMT).
Methods
Printlets formulation of PMT were developed by screening design by varying laser scanning speed, Kollidon® VA 64, polyvinylpyrrolidone, and disintegrant.
Results
Laser scanning speed, Kollidon® VA, and disintegrant had statistically significant effect on hardness, disintegration time, and/or dissolution (p < 0.05). Dissolution was almost 100% in 30 min. X-ray powder diffraction indicated partial amorphous transformation of the crystalline drug. Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p > 0.05).
Conclusion
Clinical performance of the printlets would be similar to the compressed tablets.
Taylor & Francis Online